


RealRate

PHARMACEUTICAL 2019

GYRE THERAPEUTICS INC. Rank 26 of 363









RealRate

PHARMACEUTICAL 2019

GYRE THERAPEUTICS INC. Rank 26 of 363



The relative strengths and weaknesses of GYRE THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of GYRE THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 271%, being 235% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	123,991
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,801
Liabilities, Non-Current	0
Other Assets	543
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	174
Other Net Income	3,767
Other Revenues	6.0
Property and Equipment	386
Research and Development	21,474
Selling, General and Administrative Expense	12,354

Output Variable	Value in 1000 USD
Assets	124,920
Liabilities	4,975
Expenses	33,828
Revenues	6.0
Stockholders Equity	119,945
Net Income	-30,055
Comprehensive Net Income	-30,057
Economic Capital Ratio	271%

